03 September 2010
Keywords: Biosimilars, Biological markets, URCH, Forecasts
Article | 30 March 2010
The value of the biosimilars market segment will account for 2.6% of the biological market by 2016, forecasts a new report from URCH Publishing. However, this forecast assumes biosimilars become permitted under US law by 2012, notes the market strategy report “Biosimilars: A Growing Market - An overview of developments, companies and commercial opportunities.”
The biosimilars market segment is poorly developed but is widely expected to become a significant commercial segment over the next few years, capturing a healthy percentage share of the biologicals market. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscriptions are £60 per month, pay as you go.
Find out more details.